1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. KORSANA BIOSCIENCES INC.
Korsana Biosciences Inc.
XNAS: KRSA
45,915
XNAS Volume

XNAS 09 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Korsana Biosciences Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for Korsana Biosciences Inc share price target, revenues, EPS, net income and more

Korsana Biosciences Inc quarterly results: revenue, profit, and P&L – 13 quarter history

  • NEUTRAL

    Quarterly Revenue Korsana Biosciences Inc Jun-2026 Quarterly Revenue is $0 Million which is growth of 0% YoY.

  • NEGATIVE

    Quarterly Net Profit Korsana Biosciences Inc Jun-2026 Quarterly Net Profit is $-2 Million which is growth of -441.7% YoY.

Korsana Biosciences Inc., Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23
Operating Rev.
10.90.10.11.80.2
Cost Of Rev.
-------------
Gross Profit
-------------
⌄
1.83.21.91.91.81.51.31.31.41.61.82.74.2
Operating Profit
-1.8-3.2-0.8-1-1.7-1.50.5-1.1-1.4-1.6-1.8-2.7-4.2
000000000.10.10.10.10.1
Profit Before Tax
-1.8-3.2-0.8-1-0.3-1.40.5-0.7-1.3-1.5-1.7-5.9-4.2
Tax
-------------
⌄
-1.8-3.2-0.8-1-0.3-1.40.5-0.7-1.3-1.5-1.77.6-4.2
Diluted NI Avail to Com Stockholders Ann.
-1.8-3.2-0.8-1-0.3-1.40.5-0.7-1.3-1.5-1.77.6-4.2
Basic EPS
-3.4-5.3-1.3-2.1-0-3.91.5-2-3.7-4.3-4.921.8-12.8
Diluted EPS After ExtraOrdinary
-2.9-5.3-1.3-2.1-3.8-3.91.5-3-3.7-4.3-4.6-8.7-12.8
Number Of Shares End
5.10.60.50.55.10.40.40.40.40.40.40.40.3
Net Income Continuing Discontinued Operations
-1.8-3.2-0.8-1-0.3-1.40.5-0.7-1.3-1.5-1.77.6-4.2
Normalized Income
-17.4-3.2-0.8-1-0.2-1.40.5-1.1-1.3-1.5-1.7-2.6-4.2
Interest Income
000000000.10.10.10.10.1
Interest
-------------
Net Interest Income
000000000.10.10.10.10.1
EBIT
-18.5-3.2-0.8-1-0.2-1.50.5-1.1-1.4-1.6-1.8-2.7-4.2
EBITDA
-1.8-3.2-0.8-1-1.7-1.50.5-1.1-1.4-1.6-1.8-2.7-4.2
Reconciled Cost Of Rev.
-------------
Reconciled Depr.
----------
Profit From Continuing Operations
-1.8-3.2-0.8-1-0.3-1.40.5-0.7-1.3-1.5-1.77.6-4.2
Normalized EBITDA
-1.8-3.2-0.8-1-3-1.50.5-1.5-1.4-1.6-1.80.6-4.2
*All financials are in USD Million and price data in USD

Korsana Biosciences Inc competitor comparison and performance snapshot within industry

Korsana Biosciences Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

  • POSITIVE

    Annual Revenue Korsana Biosciences Inc Dec-2025 Annual Revenue is $2 Million which is growth of 3.7% YoY.

  • NEGATIVE

    Annual Net Profit Korsana Biosciences Inc Dec-2025 Annual Net Profit is $-4 Million which is growth of -15.4% YoY.

Korsana Biosciences Inc., Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17
-
-
 0.33.32.34.5
Cost Of Rev. Ann.
-
-
 ---------
Gross Profit Ann.
-
-
 ---------
Operating Exp. Ann.
-5.9%
-15.2%
8.737.30.19.744.757.685.2129.5115.393.9
Operating Profit Ann.
-
-
-6.8-37.3-0.1-9.7-44.4-54.3-82.9-125-115.3-93.9
78.3%
23.2%
0.11.700.40.3-00.62--
Other Exp. Ann.
-
-22%
 1.30.4-3.3-2.74.5---
PBT Ann.
-
-
-6.7-35.6-0.1-12.6-44.1-51.7-77.8-123-115.3-93.9
Tax Ann.
-
-
 ---------
⌄
-
-
-6.7-35.6-0.1-5.3-44.1-51.7-77.8-123-115.6-93.9
Diluted NI Avail to Com Stockholders Ann.
-
-
-6.7-35.6-0.1-5.3-44.1-51.7-77.8-123-115.6-93.9
EPS Ann.
-
-
 -7.1-0-15.8-141.4-184.8-358.4-628.6-592.2-481.6
Diluted EPS Ann.
-
-
 -7.1-0-15.8-141.4-184.8-358.4-628.6-592.2-481.6
Number Of Shares End
18.6%
20.1%
 0.50.40.40.30.30.20.20.2-
Total Exp. Ann.
-5.9%
-15.2%
 37.30.19.744.757.685.2129.5115.393.9
Net Income Continuing Discontinued Operations Ann.
-
-
-6.7-35.6-0.1-5.3-44.1-51.7-77.8-123-115.3-93.9
Normalized Income Ann.
-
-
-22.3-34-0-9.3-44.1-54.3-82.4-123-115.3-93.9
Interest Income Ann.
-
23.2%
0.11.700.4--0.62--
Interest Ann.
-
-
 ----0----
EBITDA Ann.
-
-
-6.8-37.3-0.1-9.7-44.3-51.2-80.6-122.3-113.7-92.2
Reconciled Cost Of Rev. Ann.
-
-
 ---------
Reconciled Depr. Ann.
-
-
 --0.10.52.32.71.51.8
Profit From Continuing Operations Ann.
-
-
-6.7-35.6-0.1-5.3-44.1-51.7-77.8-123-115.3-93.9
Normalized EBITDA Ann.
-
-
-6.8-37.3-0.1-6.3-44.3-53.8-85.2-122.3-113.7-92.2
*All financials are in USD Million and price data in USD
Operating Exp. Ann.
1Y CHG
37200%
2Y CAGR
96.1%
3Y CAGR
-5.9%
5Y CAGR
-15.2%
7Y CAGR
-14.9%
Operating Expenses Annual Cr growth is higher than historical averages.

Korsana Biosciences Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

  • POSITIVE

    Total Shareholders Fund Korsana Biosciences Inc Dec-2025 Total Shareholders Fund is $9 Million which is growth of 2.7% YoY.

  • POSITIVE

    Total Assets Korsana Biosciences Inc Dec-2025 Total Assets is $10 Million which is growth of 4.3% YoY.

Korsana Biosciences Inc., Balance Sheet, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17
104.4%
6%
154.610.113.418.159.3115.4186.57.45.5
⌄
191.7%
27.5%
188.6102.17.611.155.988.817.914
⌄
-
-
-340.111.310.548.359.597.7-10.4-8.6
Total Capitalization Ann.
-
-
-340.111.310.548.359.597.7-10.5-8.6
Tangible Assets Ann.
-
-
-340.111.310.548.359.597.7-10.4-8.6
Working Capital Ann.
170.2%
27.8%
142.1105.97.244.441.683-17-12.8
Invested Capital Ann.
-
-
-340.111.310.548.36397.7-10.5-8.6
Tangible Book Value Ann.
-
-
-340.111.310.548.359.597.7-10.5-8.6
Borrowings Ann.
-
-
----45.773.9--
Net Debt Ann.
-
-
---------
Share Issued Ann.
433.3%
196.1%
45.545.50.40.30.30.20.20.20.2
Number Of Shares End
18.6%
20.1%
0.50.40.40.30.30.20.20.2-
*All financials are in USD Million and price data in USD
Total Assets Ann.
1Y CHG
1430.7%
2Y CAGR
239.7%
3Y CAGR
104.4%
5Y CAGR
6%
7Y CAGR
54.4%
Total Assets Annual growth is higher than historical averages.
Total Current Liabilities Ann.
1Y CHG
12400%
2Y CAGR
144%
3Y CAGR
18%
5Y CAGR
-6%
7Y CAGR
-5%
Total Current Liabilities Annual Cr growth is higher than historical averages.

Korsana Biosciences Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

  • NEGATIVE

    Book Value Per Share Korsana Biosciences Inc Book Value Per Share is $17 which is growth of -22.5% YoY.

  • NEUTRAL

    ROE Korsana Biosciences Inc ROE is 0% which is growth of 0% YoY.

Korsana Biosciences Inc., Ratios, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17
RoA Ann. %
-
-
--26.64%-33.47%-113.88%-59.12%-51.55%-126.89%-1,795.68%-1,717.04%
ROE Ann. %
-
-
--30.36%-48.42%-150.19%-95.87%-98.97%-281.86%--
ROIC %
-
-
-6-14.9-53.5-20.6-16.9-14.6--
OPM Ann. %
-
-
----14,940.07%-1,635.96%-3,612.11%-2,774.28%--
Inventory Turnover Ratio Ann.
-
-
---------
Asset Turnover Ann. %
-
-
-0.2-0000.1--
Working Capital Turnover Ann.
-
-
00.10.10.1
Quick Ratio Ann.
-
-
-5.23.61.84.93.25.3--
Current Ratio Ann.
-
-
-5.83.91.953.55.60.10.1
Interest Coverage Ratio Ann.
-
-
-----3,226.9----
LT Debt To Equity Ann.
-
-
-----0.70.7--
*All financials are in USD Million and price data in USD

Korsana Biosciences Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

  • POSITIVE

    Cash From Operating Activity Korsana Biosciences Inc Dec-2025 Cash From Operating Activity is $-3 Million which is growth of 23.5% YoY.

  • NEUTRAL

    Net Cash Flow Korsana Biosciences Inc Dec-2025 Net Cash Flow is $0 Million which is growth of 0% YoY.

Korsana Biosciences Inc., Cash Flow, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17
-
-
-22.40-5.5-40.6-36.5-72.5-102.2-97.5-81.2
-
-
---1.50-6.7-3.4-1.4
-
42.7%
166.410.15030.828.1211.6100.982.6
Cash Plus Cash Eqv. End Of Year Ann.
125.7%
21.5%
154.110.17.613.45458.2102.6
Net Increase In Cash Plus Cash Eqv.s Ann.
-
-
14410.1-5.8-40.6-4.3-44.4102.6--
Cash Plus Cash Eqv. Begin Of Year Ann.
-42.8%
-37.1%
10.113.45458.2102.6
Income Tax Paid Supplemental Data Ann.
-
-
---------
Interest Paid Supplemental Data Ann.
-
-
---------
Capex Ann.
-
-
-----0-1.5-6.9-3.4-1.4
Issuance Of Capital Stock Ann.
-
46.8%
165.610-30.524.3175--
Issuance Of Debt Ann.
-
-
----3.5---
Repayment Of Debt Ann.
-
-
---------
Repurchase Of Capital Stock Ann.
-
-
-0.1--------
Free Cash Flow Ann.
-
-
-22.40-21.3-40.6-36.5-74-109.1-100.9-82.6
*All financials are in USD Million and price data in USD
Cash from Financing Act. Ann.
1Y CHG
1547.5%
2Y CAGR
476.9%
5Y CAGR
42.7%
7Y CAGR
7.4%
Cash from Financing Annual Activity growth is stable compared to historical averages.